Patents by Inventor Farshid Dayyani

Farshid Dayyani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TIMP1 AS A MARKER FOR CHOLANGIOCARCINOMA
    Publication number: 20230305010
    Abstract: The present invention relates to an in vitro method for assessing cholangiocarcinoma in a patient sample, comprising the steps of: a) determining the level of tissue inhibitor of metalloproteinase-1 (TIMP1) in the patient sample, wherein the patient sample is selected from a group consisting of serum, plasma and whole blood sample from an individual, b) comparing the level of TIMP1 determined in step (a) with a reference level of TIMP1, and c) assessing cholangiocarcinoma in the patient sample by comparing the level determined in step (a) to the reference level of TIMP1, wherein an increased level of TIMP1 compared to the reference level of TIMP1 is indicative for cholangiocarcinoma in the patient sample. Further, the present invention relates to an in vitro method for assessing cholangiocarcinoma comprising TIMP1 and MMP2, the use of TIMP1 and optionally MMP2 in the in vitro assessment of CCA, and a kit for performing the said methods.
    Type: Application
    Filed: May 1, 2023
    Publication date: September 28, 2023
    Inventors: Farshid Dayyani, Anika Mang, David Morgenstern, Vinzent Rolny, Magdalena Swiatek-De Lange
  • Methods of identifying an individual to be treated by chemotherapy based on cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) marker molecules and related uses
    Patent number: 11402381
    Abstract: The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: August 2, 2022
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Friedemann Krause, Vinzent Rolny, Farshid Dayyani, Achim Escherich, Birgit Wehnl, Ying He, Julia Riedlinger, Felix Herth, Thomas Muley
  • METHODS OF DETECTING A RELAPSE OF A LUNG ADENOCARCINOMA BASED ON MARKER HUMAN EPIDIDYMIS PROTEIN 4 (HE4) AND RELATED USES
    Publication number: 20180292410
    Abstract: The present disclosure relates to a method of detecting a relapse of a lung adenocarcinoma in an individual based on marker human epididymis protein 4 (HE4) and optionally Cytokeratin-19 fragments (Cyfra21-1) as well as the use of a marker in the in vitro assessment of a relapse of a lung adenocarcinoma.
    Type: Application
    Filed: June 14, 2018
    Publication date: October 11, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Farshid Dayyani, Friedemann Krause, Achim Escherich, Birgit Wehnl, Ying He, Vinzent Rolny, Sandra Rutz, Thomas Muley, Felix Herth, Julia Riedlinger
  • METHODS OF IDENTIFYING AN INDIVIDUAL TO BE TREATED BY CHEMOTHERAPY BASED ON MARKER MOLECULES AND RELATED USES
    Publication number: 20180231557
    Abstract: The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.
    Type: Application
    Filed: April 13, 2018
    Publication date: August 16, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Friedemann Krause, Vinzent Rolny, Farshid Dayyani, Achim Escherich, Birgit Wehnl, Ying He, Julia Riedlinger, Felix Herth, Thomas Muley